Skip to main content

Advertisement

SpringerLink
Log in

Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Introduction: In patients with limited disease small cell lung cancer (LD-SCLC) treated with concurrent chemoradiotherapy (CCRT), long-term survival data have not been fully evaluated. Moreover, the association between long-term prognosis and prognostic factors has not been sufficiently investigated. Methods: In this retrospective study, we evaluated the efficacy of CCRT in 120 patients with LD-SCLC with a plan for curative CRT using concurrent accelerated hyperfractionated radiotherapy. Results: The patients had a median age of 65.5 years, predominantly male (73%), and had clinical stage III disease (80%). The median follow-up time for overall survival (OS) was 72.2 months, median OS was 42.5 months, and the 3-year and 5-year survival rates were 52.4% and 41.8%, respectively. The median progression-free survival (PFS) was 12.5 months, and the 3-year and 5-year PFS rates were 37.6% and 33.6%, respectively. The 5-year OS rates of patients who achieved PFS at each time point were 70.9%, 83.6%, and 91.9% at 12, 24, and 36 months, respectively. The gradual increase in the 5-year OS rate following PFS extension and initial depression of the Kaplan–Meier curve showed disease progression frequently occurred in the first 2 years after initiation of CCRT. The Cox proportional hazards model showed no significant factors correlated with long-term survival through univariate and multivariate analyses. Although the prognostic factors associated with long-term prognosis in LD-SCLC were not identified, the 5-year survival rate was 41.8%, and among patients without disease progression at 2 years, the 5-year survival rate was 83.6%. Conclusion: These data suggested that the prognosis of patients with LD-SCLC was improving.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

All data and material are available on reasonable request.

Code availability

Not applicable.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clinic 68(6):394–424

  2. Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF et al (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 390(10100):1151–1210

    Article  Google Scholar 

  3. Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2021) SEER Cancer Statistics Review, 1975–2018, National Cancer Institute. Bethesda, MD, April 2021 [Available from: https://seer.cancer.gov/csr/1975_2018/]

  4. Devesa SS, Bray F, Vizcaino AP, Parkin DM (2005) International lung cancer trends by histologic type: Male: Female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117(2):294–299

    Article  CAS  Google Scholar 

  5. Oronsky B, Reid TR, Oronsky A, Carter CA (2017) What’s New in SCLC? A Review Neoplasia 19(10):842–847

    Article  CAS  Google Scholar 

  6. Bernhardt EB, Jalal SI (2016) Small Cell Lung Cancer. Springer International Publishing 301–22

  7. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al (2006) Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database. J Clin Oncol 24(28):4539–4544

    Article  Google Scholar 

  8. Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis J Clin Oncol 10(6):890–895

    CAS  PubMed  Google Scholar 

  9. Pignon J-P, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL et al (1992) A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer. N Engl J Med 327(23):1618–1624

    Article  CAS  Google Scholar 

  10. Lu H, Fang L, Wang X, Cai J, Mao W (2014) A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer. Molecular and Clinical Oncology 2(5):805–810

    Article  Google Scholar 

  11. Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A et al (2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 18(8):1116–1125

    Article  Google Scholar 

  12. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R et al (1999) Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide. N Engl J Med 340(4):265–271

    Article  CAS  Google Scholar 

  13. Fujii M, Hotta K, Takigawa N, Hisamoto A, Ichihara E, Tabata M et al (2012) Influence of the timing of tumor regression after the initiation of chemoradiotherapy on prognosis in patients with limited-disease small-cell lung cancer achieving objective response. Lung Cancer 78(1):107–111

    Article  Google Scholar 

  14. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, Kester A, Rutten I, Lambin P (2007) Timing of chest radiotherapy in patients with limited stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev 33(5):461–473

    Article  Google Scholar 

  15. Turrisi AT 3rd (1994) Platinum combined with radiation therapy in small cell lung cancer: focusing like a laser beam on crucial issues. Semin Oncol 21(3 Suppl 6):36–42

    PubMed  Google Scholar 

  16. Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF et al (1996) Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 14(3):806–813

    Article  CAS  Google Scholar 

  17. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S et al (2002) Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20(14):3054–3060

    Article  CAS  Google Scholar 

  18. Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer Statistics 2021. CA: A Cancer J Clinic 71(1):7–33

  19. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 379(23):2220–2229

    Article  CAS  Google Scholar 

  20. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929–1939

    Article  CAS  Google Scholar 

  21. Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G et al (2020) Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. Clin Lung Cancer 21(2):e84–e88

    Article  CAS  Google Scholar 

  22. Akamatsu H, Mori K, Naito T, Imai H, Ono A, Shukuya T et al (2014) Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer 14(1):18

    Article  Google Scholar 

  23. Kalemkerian GP (2016) Small Cell Lung Cancer. Semin Respir Crit Care Med 37(5):783–796

    Article  Google Scholar 

  24. Badzio A, Kurowski K, Karnickamlodkowska H, Jassem J (2004) A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 26(1):183–8

  25. Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM, Deming RL et al (2009) Prognostic factors differ by tumor stage for small cell lung cancer. Cancer 115(12):2721–2731

    Article  CAS  Google Scholar 

  26. Hermes A, Gatzemeier U, Waschki B, Reck M (2010) Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – A retrospective single institution analysis. Respir Med 104(12):1937–1942

    Article  Google Scholar 

  27. Reymen B, Van Loon J, van Baardwijk A, Wanders R, Borger J, Dingemans AM et al (2013) Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer. Int J Radiat Oncol Biol Phys 85(5):1319–1324

    Article  Google Scholar 

  28. Wolf M, Holle R, Hans K, Drings P, Havemann K (1991) Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): The role of sex as a predictor for survival. Br J Cancer 63(6):986–992

    Article  CAS  Google Scholar 

  29. Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z et al (2010) Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer 67(2):221–226

    Article  Google Scholar 

  30. Ball DL, Fisher RJ, Burmeister BH, Poulsen MG, Graham PH, Penniment MG et al (2013) The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: A prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol 106(3):305–11

  31. Karin M, Taugner J, Käsmann L, Eze C, Roengvoraphoj O, Tufman A et al (2020) Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis. Cancers 12(10):3035

    Article  CAS  Google Scholar 

  32. Koo TR, Moon SH, Lim YJ, Kim JY, Kim Y, Kim TH et al (2004) The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Radiother Oncol 9(1)

Download references

Acknowledgements

We would like to thank Editage [http://www.editage.com] for editing and reviewing this manuscript for English language.

Funding

This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-Sho Sunto-Gun, Shimonagakubo Shizuoka, 1007411-8777, Japan

    Kosei Doshita, Hirotsugu Kenmotsu, Shota Omori, Hiroaki Kodama, Naoya Nishioka, Eriko Miyawaki, Yuko Iida, Taichi Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami & Toshiaki Takahashi

  2. Department of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan

    Kosei Doshita & Takeshi Kaneko

  3. Radiation and Proton Therapy Center, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, 411-8777, Japan

    Yuya Tabuchi & Hideyuki Harada

  4. Clinical Research Center, Shizuoka Cancer Center, Nagaizumi-Cho Sunto-Gun, Shimonagakubo Shizuoka, 1007411-8777, Japan

    Takanori Kawabata & Keita Mori

Authors
  1. Kosei Doshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hirotsugu Kenmotsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shota Omori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuya Tabuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takanori Kawabata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroaki Kodama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoya Nishioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eriko Miyawaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuko Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Taichi Miyawaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nobuaki Mamesaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Haruki Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ryo Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kazushige Wakuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Akira Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Tateaki Naito
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Haruyasu Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Keita Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Hideyuki Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Takeshi Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Toshiaki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KD and KH wrote the manuscript. KD and YT researched data. KH reviewed and edited the manuscript. KT is a professional biostatistician and responsible for statistical analysis. All authors reviewed, approved the final version of the manuscript.

Corresponding author

Correspondence to Hirotsugu Kenmotsu.

Ethics declarations

Ethics approval

All procedures performed in the human participant were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent to participate

For this type of study, formal consent is not required. We have also applied an opt-out method to obtain consent for this study by posting a document about this study. The document has been approved by the institutional ethics review board of Shizuoka Cancer Center.

Consent for publication

Not applicable.

Conflicts of interest

The authors have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Doshita, K., Kenmotsu, H., Omori, S. et al. Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis. Invest New Drugs 40, 411–419 (2022). https://doi.org/10.1007/s10637-021-01183-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-021-01183-6

Keywords

Search

Navigation